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Abstract
Importance—BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its
role in PTC-related patient mortality has not been established.
Objective—To investigate the relationship between BRAF V600E mutation and PTC-related
mortality.
Design, Setting, and Participants—Retrospective study of 1849 patients (1411 women and
438 men) with a median age of 46 years (interquartile range, 34–58 years) and an overall median
follow-up time of 33 months (interquartile range, 13–67 months) after initial treatment at 13
centers in 7 countries between 1978 and 2011.
Main Outcomes and Measures—Patient deaths specifically caused by PTC.
Results—Overall, mortality was 5.3% (45/845; 95% CI, 3.9%–7.1%) vs 1.1% (11/1004; 95% CI,
0.5%–2.0%) (P<.001) in BRAF V600E–positive vs mutation-negative patients. Deaths per 1000
person-years in the analysis of all PTC were 12.87 (95% CI, 9.61–17.24) vs 2.52 (95% CI, 1.40–
4.55) in BRAF V600E–positive vs mutation-negative patients; the hazard ratio (HR) was 2.66
(95% CI, 1.30–5.43) after adjustment for age at diagnosis, sex, and medical center. Deaths per
1000 person-years in the analysis of the conventional variant of PTC were 11.80 (95% CI, 8.39–
16.60) vs 2.25 (95% CI, 1.01–5.00) in BRAF V600E–positive vs mutation-negative patients; the
adjusted HR was 3.53 (95% CI, 1.25–9.98). When lymph node metastasis, extrathyroidal invasion,
and distant metastasis were also included in the model, the association of BRAF V600E with
mortality for all PTC was no longer significant (HR, 1.21; 95% CI, 0.53–2.76). A higher BRAF
V600E–associated patient mortality was also observed in several clinicopathological
subcategories, but statistical significance was lost with adjustment for patient age, sex, and
medical center. For example, in patients with lymph node metastasis, the deaths per 1000 person-
years were 26.26 (95% CI, 19.18–35.94) vs 5.93 (95% CI, 2.96–11.86) in BRAF V600E–positive
vs mutation-negative patients (unadjusted HR, 4.43 [95% CI, 2.06–9.51]; adjusted HR, 1.46 [95%
CI, 0.62–3.47]). In patients with distant tumor metastasis, deaths per 1000 person-years were
87.72 (95% CI, 62.68–122.77) vs 32.28 (95% CI, 16.14–64.55) in BRAF V600E–positive vs
mutation-negative patients (unadjusted HR, 2.63 [95% CI, 1.21–5.72]; adjusted HR, 0.84 [95%
CI, 0.27–2.62]).
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Conclusions and Relevance—In this retrospective multicenter study, the presence of the
BRAF V600E mutation was significantly associated with increased cancer-related mortality
among patients with PTC. Because overall mortality in PTC is low and the association was not
independent of tumor features, how to use BRAF V600E to manage mortality risk in patients with
PTC is unclear. These findings support further investigation of the prognostic and therapeutic
implications of BRAF V600E status in PTC.
Papillary thyroid cancer (PTC) is the most common endocrine malignancy and accounts for
85% to 90% of all thyroid cancers. There are several variants of PTC, the majority of which
are conventional PTC and follicular variant PTC, with the former typically showing
papillary structures and the latter follicular structures in addition to the characteristic nuclear
features of PTC. The overall 5-year patient survival rate for PTC is 95% to 97%.2 A major
clinical challenge is how to reliably distinguish patients who need aggressive treatments to
reduce mortality from those who do not. This represents a widely controversial issue in
thyroid cancer medicine, particularly because of the low overall mortality of this cancer. The
issue has become even more challenging given the high annual incidence of PTC.1,2 Several
clinicopathological risk factors have been used in the stratification of PTC, including older
age of patients at diagnosis, larger tumor size, cervical lymph node metastasis (LNM),
extrathyroidal invasion, distant metastasis, and high levels on disease staging.3–5 Although
these factors are known to be associated with a higher risk of progression of PTC, they often
lack accuracy in helping tailor the extent of treatment of PTC to balance treatment-
associated benefit and risk.
The T1799A nucleotide transversion in the BRAF gene (NM_004333) is a prominent
oncogenic mutation in PTC6–11 and occurs, on average, in 45% of cases.12 This mutation
causes a valine–to–glutamic acid change in codon 600 of the BRAF protein, resulting in
BRAF V600E, which possesses elevated serine/threonine protein kinase activities and
constitutively activates the mitogen-activated protein kinase signaling pathway in human
cancer.13 Many studies have shown an association of the BRAF V600E mutation with
aggressive clinicopathological characteristics of PTC, including LNM, extrathyroidal
invasion, loss of radioiodine avidity, and, hence, failure of radioiodine treatment and disease
recurrence.14,15 Consequently, the BRAF V600 Emutation has drawn considerable attention
and interest as a potential prognostic factor for PTC. However, the clinical significance of
this mutation in PTC-related mortality has not been established. We undertook the present
multi-center study to examine and define the association between the BRAF V600
Emutation and PTC-related mortality.
The Box contains a glossary of terms used in this article.
Box
Glossary of Terms
Methylation
Covalent attachment of methyl groups to DNA, usually at cytosine bases. Methylation
can reduce transcription from a gene and is a mechanism in X-chromosome inactivation
and imprinting.
Oncogene
A gene, 1 or more forms of which is associated with cancer. Many oncogenes are
involved, directly or indirectly, in controlling the rate of cell growth.
Transversion
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The substitution of a purine for a pyrimidine nucleotide or vice versa (eg, an A for a C or
T) in a DNA sequence.
For a complete list of genomic terms, see the Appendix in this issue.
METHODS
This study was conducted at 13 medical centers in 7 countries, including the Johns Hopkins
Medical Institutions, University of Pittsburgh Medical Center, and Memorial Sloan-
Kettering Cancer Center in the United States; medical centers at the University of Pisa,
University of Perugia, University of Milan, and University of Padua in Italy; Kanagawa
Cancer Center, Yokohama, Japan; Maria Sklodowska-Curie Memorial Cancer Centre and
Institute of Oncology in Poland; medical centers at Griffith Medical School and University
of Sydney in Australia; Hospital La Paz Health Research Institute in Spain; and the Institute
of Endocrinology, Prague, Czech Republic.
Study Patients
All patients had been treated and followed up for PTC at the participating institutions and
their collaborating medical centers. Patients at each center were consecutively selected from
different periods at the 13 centers, which overall spanned 1978–2011. All patients were
treated with total thyroidectomy for PTC, and therapeutic neck dissection was performed in
patients with standard indications. Standard pathological diagnoses of PTC were based on
World Health Organization criteria and documented in peer-reviewed publications.16–29
Postoperative treatments included, as guided by standard criteria, conventional thyrotropin
suppression at appropriate levels and radioiodine I 131 ablation (eTable 1; available at http://
www.jama.com), except for Kanagawa Cancer Center, where no radioiodine I 131 treatment
was used for thyroid cancer patients. Follow-up or survival time was defined as the time
from the initial surgical treatment to patient death due to PTC or to the most recent clinic
visit.
Study Design
This was a retrospective study approved by the institutional review boards of each center,
with written informed patient consent obtained where required; patient consent was waived
in some cases following institutional review board–approved procedures in the collection of
pathological data. The study involved the use of only thyroid tumor tissues and
clinicopathological information of patients. The BRAF V600E mutation status of primary
PTC tumors was determined after surgical and medical (eg, radioiodine) treatments in all
cases and did not affect decisions on selection of treatments. Genomic DNA isolated from
primary PTC tumors was used to analyze the sequence of exon 15 of the BRAF gene for
BRAF V600E as described in published studies.16–29 Clinicopathological information was
obtained from the medical records using a uniform protocol designed for this study.
Papillary thyroid cancer–specific death was defined as death that occurred as a result of
incurable advanced PTC disease that invaded and compromised vital organs. Patient data
from the 13 centers were pooled for the analysis of the relationship of BRAF V600E with
PTC-specific mortality in various clinicopathological categories.
Statistical Analyses
Papillary thyroid cancer–specific mortality was calculated by dividing the number of deaths
due to PTC by the total number of patients. The Fisher exact test was used to compare
mortality by BRAF V600E mutation status. Rates per person-year were calculated by
dividing the number of PTC-specific deaths by the total follow-up time, and Poisson
regression was used to calculate the 95% confidence intervals. Kaplan-Meier survival curves
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and log-rank tests, censoring patients at the time of last follow-up or 12 years, and Cox
proportional hazards regression analyses, censoring patients at the time of last follow-up,
were used to compare PTC-specific survival by BRAF V600E mutation status. Proportional
hazards regressions were adjusted for age at diagnosis, sex, and medical center. A second
model was also used to additionally adjust for LNM, extrathyroidal invasion, and distant
metastasis. The covariates were tested for the proportional hazards assumption using the
“assess” statement in SAS version 9.3 (SAS Institute Inc). As medical centers violated the
proportional hazards assumption, stratified models were used. Subgroup analyses were not
adjusted for multiple comparisons and should be considered exploratory. Additive
interactions of BRAF V600E mutation status with other factors on the crude death rates
were tested using the synergy index and 95% confidence intervals described by Hosmer and
Lemeshow.30 Exact binomial confidence intervals for mortality percentages were calculated
using Stata/IC version 12.1 (Stata Corp). All other analyses were performed using SAS
version 9.3. All reported P values are 2-sided and significance was set at P<.05. The P
values from the log-rank tests comparing each stratum with the lowest risk stratum were
adjusted for multiple comparisons using the Dunnett test.
RESULTS
Relationship Between BRAF V600E and PTC-Related Mortality
The number, sex, and age of patients from each center and country are summarized in Table
1. A total of 1849 patients (1411 women and 438 men) with a median age of 46 years
(interquartile range [IQR], 34–58 years) were included, with an overall median follow-up
time of 33 months (IQR, 13–67 months) after the initial treatment. Median follow-up time
for surviving patients did not differ between BRAF V600E–positive patients (30 [IQR, 14–
63] months) and BRAF V600E–negative patients (36 [IQR, 12–67] months) (P=.30). The
overall prevalence of BRAF V600E was 45.7% (845/1849; 95% CI, 43.4%–48.0%) (Table
1), which is within the range of published BRAF V600E mutation rates.12,14,15 There were
56 PTC-related deaths among the 1849 patients, representing an overall mortality of 3.0%
(95% CI, 2.3%–3.9%), which is consistent with the general mortality rate of PTC.2 Among
these deaths, 45 cases (80.4%) were positive for BRAF V600E. Mortality percentages and
deaths per 1000 person-years for different types of PTC are reported in Table 2. The overall
mortality of all PTC cases was 5.3% (45/845; 95% CI, 3.9%–7.1%) in BRAF V600E–
positive patients vs 1.1% (11/1004; 95% CI, 0.5%–2.0%) in mutation-negative patients (P<.
001). The total follow-up for all PTC cases was 7856.75 person-years. Deaths per 1000
person-years on the analysis of all PTC cases were 12.87 (95% CI, 9.61–17.24) vs 2.52
(95% CI, 1.40–4.55) in BRAF V600E–positive vs mutation-negative patients; the hazard
ratio (HR) was 2.66 (95% CI, 1.30–5.43) after adjustment for age at diagnosis, sex, and
stratification by medical center. Deaths per 1000 person-years for patients with the
conventional variant of PTC were 11.80 (95% CI, 8.39–16.60) vs 2.25 (95% CI, 1.01–5.00)
in BRAF V600E–positive vs mutation-negative patients; the adjusted HR was 3.53 (95% CI,
1.25–9.98) (Table 2). No significant result was observed for the follicular variant PTC
group, which had low numbers of cases and patient deaths (adjusted HR, 1.67; 95% CI,
0.06–47.49). When the aggressive tumor features of LNM, extrathyroidal invasion, and
distant metastasis were also included in the model, the association of BRAF V600E with
mortality was no longer statistically significant (for all PTC, HR, 1.21 [95% CI, 0.53–2.76];
for conventional PTC, HR, 1.51 [95% CI, 0.50–4.57]). Kaplan-Meier survival curves for all
PTC and conventional PTC cases are shown in Figure 1. BRAF V600E–positive patients
had significantly poorer survival in each analysis.
Papillary thyroid cancer–related mortality, total person-years, and rates by BRAF V600E
mutation status in various clinicopathological subcategories are presented in Table 3. Higher
mortality percentages and deaths per 1000 person-years were seen with BRAF V600E
Xing et al. Page 5
JAMA. Author manuscript; available in PMC 2013 October 05.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
within most of the categories, including among patients with distant metastasis and
advanced American Joint Committee on Cancer stage IV disease, in which the highest
mortality percentages and deaths per 1000 person-years were seen. However, after
adjustment for age, sex, and medical center, the HRs were no longer statistically significant
in some of these stratified categories. The association of BRAF V600E with mortality
among patients with disease stages I, II, and III was not statistically significant. When
tumors were stratified by size, the absolute magnitude of mortality increased from smaller to
larger tumors, particularly in the BRAF V600E–positive groups. BRAF V600E had a
significant association with mortality percentages of micro-PTC (≤1.0 cm), but the absolute
mortality was low and the adjusted HRs were not significant (Table 3).
We found that the therapeutic doses of radioiodine used in the treatment of patients were
comparable between the BRAF V600E–positive and mutation-negative groups, except in
some centers where the BRAF V600E group received higher doses (eTable 1).
Interaction of BRAF V600E With Conventional Clinicopathological Risk Factors
We observed a significant additive interaction of BRAF V600E with several conventional
clinicopathological risk factors in affecting PTC-related mortality, as reflected by a
significant synergy index (eTable 2). These included LNM, distant metastasis, stage IV
disease, and patient age at diagnosis. The synergy index was not statistically significant for
extrathyroidal invasion. As shown in Table 3, deaths per 1000 person-years for coexisting
LNM and BRAF V600E were 26.26 (95% CI, 19.18–35.94), whereas they were 5.93 (95%
CI, 2.96–11.86) in LNM-positive but BRAF V600E–negative patients and 2.43 (95% CI,
0.91–6.47) in LNM-negative but BRAF V600E–positive patients. Deaths per 1000 person-
years for coexisting distant metastatic disease and BRAF V600E were 87.72 (95% CI,
62.68–122.77), whereas they were 32.28 (95% CI, 16.14–64.55) in distant metastasis–
positive but BRAF V600E–negative patients and 3.54 (95% CI, 1.96–6.39) in distant
metastasis–negative but BRAF V600E–positive patients. Similarly, with coexistence of
stage IV disease and BRAF V600E, deaths per 1000 person-years were 69.97 (95% CI,
50.91–96.16), whereas they were 32.38 (95% CI, 17.42–60.18) in BRAF V600E–negative
patients with stage IV disease and 2.08 (95% CI, 0.93–4.62) in BRAF V600E-positive
patients without stage IV disease. The common pattern of these relationships is that the
mortality associated with coexistence of BRAF V600E and a conventional risk factor was
higher than the addition of the 2 types of mortality associated with either alone, further
supporting the synergistic additive interactions of BRAF V600E with these risk factors
demonstrated by the synergy index test (eTable 2). This pattern of interaction of BRAF
V600E with clinicopathological factors in affecting PTC-related mortality was also reflected
in the Kaplan-Meier survival curves (Figure 2).
BRAF V600E and Patient Age in PTC-Related Mortality
As shown in Table 3, in both BRAF V600E–positive and mutation-negative patients,
mortality increased with age, and this was particularly evident in BRAF V600E–positive
patients. Specifically, deaths per 1000 person-years in BRAF V600E–positive patients
younger than 45 years and 45 years or older were 3.19 (95% CI, 1.33–7.66) and 20.75 (95%
CI, 15.22–28.29), respectively, vs 0.81 (95% CI, 0.20–3.24) and 4.76 (95% CI, 2.48–9.14)
in BRAF V600E–negative patients in these age groups with a significant synergistic
interaction (synergy index, 3.15; 95% CI, 1.37–7.27) (eTable 2). Deaths per 1000 person-
years in BRAF V600E–positive patients younger than 60 years and 60 years or older were
5.27 (95% CI, 3.12–8.89) and 37.03 (95% CI, 26.04–52.65), respectively, vs 1.34 (95% CI,
0.56–3.21) and 9.68 (95% CI, 4.35–21.56) in BRAF V600E–negative patients in these age
groups, with a significant synergistic interaction (synergy index, 3.40; 95% CI, 1.52–7.62).
Thus, these results showed a significant additive interaction of BRAF V600E with older
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patient age on mortality due to PTC. This positive interaction of BRAF V600E with patient
age in affecting PTC mortality was also shown in Kaplan-Meier survival curves (Figure 3).
When analyzing patients with the conventional PTC variant, BRAF V600E was similarly
associated with higher patient mortality within various clinicopathological risk categories
(eTable 3).
Mortality in BRAF V600E Mutation-Negative Conventionally Low-Risk Patients
As shown in Table 3, the overall mortality was low in conventionally low-risk patients; ie,
those with tumor size of 1.0 cm or smaller, stage I to III diseases, or age younger than 45
years. Mortality was lowest in the BRAF V600E–negative patients of these groups, ranging
from 0 to 0.81 (95% CI, 0.20–3.24) deaths per 1000 person-years. A uniform 0 mortality
was observed in BRAF V600E–negative patients in these groups when the analysis was
restricted to only conventional PTC (eTable 3). A moderate increase in mortality was seen in
the presence of BRAF V600E in some of these groups but was not statistically significant
(Table 3 and eTable 3).
DISCUSSION
In this multicenter study, we found a significant association of BRAF V600E mutation with
PTC-related mortality, both in patients with all types of PTC and in patients with
conventional PTC. The majority of the mortality cases (80.4%) harbored this mutation.
These results suggest the importance of BRAF V600E in PTC-related mortality. We also
observed a significant additive interaction between BRAF V600E and several conventional
clinicopathological factors affecting the magnitude of PTC-related mortality, including older
patient age at diagnosis, LNM, distant metastasis, and advanced disease (stage IV). Most of
these factors alone had only a modest mortality risk, which was significantly increased by
coexisting BRAF V600E. Thus, the widely known mortality risk associated with the
conventional high-risk clinicopathological factors of PTC is closely related to the coexisting
BRAF V600E mutation.
The significance of the association of BRAF V600E with mortality needs to be interpreted
from the perspective of absolute risk. For example, as shown in Table 3, BRAF V600E in
patients without distant metastasis was associated with an increase in mortality from 0.3%
(3/944) to 1.4% (11/772) (P=.01), whereas it was increased in patients with distant
metastasis from 18.2% (8/44) to 51.5% (34/66) (P<.001). Although the difference was
statistically significant in both situations, there was only 1 additional patient death in the
former vs 33 additional deaths in the latter associated with BRAF V600E in 100 patients. In
some of the conventionally low-risk categories, such as tumors of 1.0 cm or smaller, BRAF
V600E was also associated with mortality, consistent with previous findings that this
mutation could be associated with aggressive tumor features even in conventionally low-risk
patients.14,18,31 In such low-risk categories, however, the absolute mortality rate is low. It is
also clinically important to note that absence of the BRAF V600E mutation was associated
with a mortality of nearly 0% in conventionally low-risk patients.
The explanation for a role of BRAF V600E in PTC-related mortality likely lies in the
molecular mechanisms by which BRAF V600E promotes aggressive molecular patho
genesis of PTC. For example, BRAF V600E causes de differentiation of PTC, resulting in
the loss of expression of thyroid genes involved in thyroid iodide concentration and, hence,
failure of radioiodine treatment.14,15 BRAF V600E strongly up-regulates many classic
angiogenic and tumor-promoting molecules (eg, vascular endothelial growth factor, matrix
metalloproteinases, c-MET, and nuclear transcription factor κB)and is associated with
hypermethylation and, hence, inactivation of tumor suppressor genes (eg, tissue inhibitor of
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matrix metalloproteinase 3, death-associated protein kinase, and SLC5A8)14,31 as well as
extracellular protumor microenvironmental changes.32 BRAF V600E causes genome-wide
alterations in methylation and, hence, aberrant expression of prominent genes in thyroid
cancer33 as well as in melanoma.34 There are also other molecular derangements and
signaling path-way aberrations caused by BRAF V600E in thyroid cancer.35
It is likely that through these unique molecular mechanisms and others as yet unknown,
BRAF V600E promotes aggressive tumor behaviors such as LNM, tumor invasion, and
distant metastasis; silences thyroid iodide-metabolizing genes and renders the tumor
resistant to radioiodine treatment; and expedites tumor progression, hence aggravating the
risk of PTC-related mortality, which is ultimately caused by these aggressive tumor
behaviors. Thus, BRAF V600E cannot be independent of such tumor behaviors in affecting
patient mortality. In fact, when we adjusted for these tumor behaviors, the association with
BRAF V600E was no longer statistically significant, indicating that these tumor behaviors
may lie in a causal pathway. In contrast, stratification by center and adjustment for patient
age and sex did not remove the significant association of BRAF V600E with mortality in
either the overall analysis of all PTC or the analysis of conventional PTC.
The large number of cases and multicenter design with worldwide geographic reach
represent a major strength of this study. The treatments, including total thyroidectomy,
therapeutic neck dissection, and appropriate postoperative thyrotropin suppression, were
pursued following accepted standards at the participating centers, and the pathological
diagnoses of tumors were formally documented.16–29 Although patient follow-up durations
after the initial treatment varied between centers, this was not different by BRAF V600E
status within centers and in the overall analysis. Moreover, we used Cox proportional
hazards regression and Kaplan-Meier survival analysis as well as person-year mortality rates
to account for different durations. Most of the known relationship patterns of conventional
clinicopathological risk factors with PTC-related mortality were accurately reproduced in
the present study, supporting its validity. At some centers, BRAF V600E patients received
higher doses of radioiodine treatments when retrospectively analyzed after BRAF V600E
testing. This likely reflects that BRAF V600E patients tended to present with more
aggressive clinicopathological behaviors of PTC, prompting more aggressive radioiodine
treatment. This may have caused an underestimate of the association of BRAF V600E with
PTC mortality in the present study, as radioiodine treatment has been associated with
decreased mortality of thyroid cancer in conventionally high-risk patients,3 which, as the
present study showed, is where BRAF V600E has the most significant association with
mortality.
There are a few limitations of the present study. First, the low number of PTC-specific
deaths, as is generally seen for PTC, reduced the power to find associations and resulted in
wide confidence intervals for some of the subcategory estimates. This was particularly an
issue in the stratified analyses. In fact, adjusted HRs lost significance in some stratified
subcategories (Table 3). This, however, partially reflects that BRAF V600E synergistically
interacts with patient age in its association with mortality and the effect of BRAF V600E
would therefore be attenuated when patient age was adjusted in the model. Additionally,
stratified analyses were performed with no adjustment for multiple comparisons because of
a relatively small number of cases. Therefore, these stratified analyses should be considered
exploratory and hypothesis generating. Second, many patients had a relatively short clinical
follow-up. This may have led to an incomplete representation by the present study of the
natural mortality course of PTC and, hence, an in accurate picture of the relationship of
BRAF V600E and PTC-related mortality. This seems to be suggested by the observation
that the association became clearer after longer follow-up. Another limitation is that we
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captured only PTC-specific deaths in our data, censoring patients who died of other causes
at the time of last follow-up. Therefore, we could not look at all-cause mortality.
In summary, in this multicenter study, the presence of the BRAF V600E mutation was
significantly associated with increased cancer-related mortality among patients with PTC.
However, overall mortality in PTC is low, and the association was not independent of tumor
behaviors. Therefore, how to use BRAF V600E for the management of mortality risk among
patients with PTC is not clear. These findings support further investigation of the prognostic
and therapeutic implications of BRAF V600E status in PTC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Kaplan-Meier Survival Curves of PTC-Specific Survival by BRAF V600E Mutation Status
Comparison of patient survival, represented by log-rank P values in each panel, was
performed between BRAF V600E–negative and BRAF V600E–positive groups for all
patients and for patients with conventional papillary thyroid cancer (PTC). Follow-up time is
truncated at 12 years.
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Figure 2.
Kaplan-Meier Survival Curves of the Interaction of BRAF V600E Mutation With
Clinicopathological Risk Factors in Affecting Disease-Specific Survival of Patients With
Papillary Thyroid Cancer
In all panels, follow-up time is truncated at 12 years. In each panel, P values are from the
log-rank test adjusted for multiple comparisons comparing each stratum with patients
negative for both the BRAF V600E mutation and the indicated clinicopathological factor.
Xing et al. Page 13
JAMA. Author manuscript; available in PMC 2013 October 05.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Kaplan-Meier Survival Curves of the Interaction of BRAF V600E Mutation With Age in
Affecting Disease-Specific Survival of Patients With Papillary Thyroid Cancer
In all panels, follow-up time is truncated at 12 years. In each panel, P values are from the
log-rank test adjusted for multiple comparisons comparing each stratum with patients
negative for both the BRAF V600E mutation and younger than 45 years (panel A) or
younger than 60 years (panel B).
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